secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002839
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma updates pipeline: CT-1119 Phase 1 start H1 2025, liver fibrosis IND in 2026
--------------------------------------------------------------------------------

- CT-1119 (mesothelin-targeted CAR-Monocyte) Phase 1 trial with tislelizumab in solid tumors expected to start H1 2025.
- Phase 1 trial to enroll up to 12 patients in China; initial safety/efficacy data anticipated Q4 2025.
- Liver fibrosis program: preclinical in 2025 to enable regulatory submission in 2026, followed by Phase 1 in 2026.
- Corporate presentation updated on company website with these pipeline milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925002839/0001104659-25-002839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465925002839/tm253058d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer